Cited by 56Ovarian function and disordersGenetic and Kidney Cyst DiseasesEndometriosis Research and Treatment

Effects of metformin in adolescents with polycystic ovary syndrome undertaking lifestyle therapy: a pilot randomized double-blind study

Open access
Ladson, Gwinnett, Dodson, William C., Sweet, Stephanie D., Archibong, Anthony E., Kunselman, Allen R., Demers, Laurence M., Lee, Peter A., Williams, Nancy I. +2 more·2011·Fertility and Sterility

Abstract

Our small study does not support the addition of metformin to the lifestyle of adolescents. Although there are favorable trends toward hyperandrogenism with metformin, these must be balanced against the increased rate of gastrointestinal side effects. However, other treatments were associated with an improved quality of life.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.fertnstert.2011.05.048

Cites

25 of 25 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Metformin may be considered when hyperinsulinemia is a dominant feature but is not a weight-loss medication per se.

    “It may be considered when hyperinsulinemia is a dominant feature but is not a weight-loss medication per se [116].”

    From Precision obesity medicine: A phenotype-guided framework for pharmacologic therapy across the lifespan (2025) · cites this paper as [116]

    The paper reports no change in weight or waist circumference after 24 weeks and concludes that its study does not support adding metformin to lifestyle therapy in adolescents with PCOS (both passages labeled Abstract; page not supplied). This supports caution about treating metformin as a weight-loss medication in this setting, but the paper does not say it should be considered when hyperinsulinemia is a dominant feature. (LLM, conf=0.83)

    Experimental — accuracy not yet measured
  • Metformin is used off-label in adolescents with insulin resistance or PCOS, with modest weight effects.

    “Metformin is used off-label in adolescents with insulin resistance or PCOS, with modest weight effects.”

    From Precision obesity medicine: A phenotype-guided framework for pharmacologic therapy across the lifespan (2025) · cites this paper as [116]

    The study reports giving metformin to adolescents with PCOS and finding no significant change in weight; the discussion describes minimal weight gain in its participants. Our copy does not establish that this use was off-label or that the study treated adolescents for insulin resistance. The weight finding supports a limited effect in this small PCOS trial, not a general claim about adolescents. (LLM, conf=0.84)

    Experimental — accuracy not yet measured
  • A meta-analysis of metformin use with and without lifestyle changes in PCOS (including two RCTs in adolescents) showed beneficial effects on BMI and menstrual cycles.

    “A meta-analysis of metformin use with and without lifestyle changes in PCOS (including two RCTs in adolescents [164, 178]) showed beneficial effects on BMI and menstrual cycles [164, 178, 179].”
  • Another RCT by Ladson et al. on 22 adolescents found no significant differences in BMI between metformin plus lifestyle and placebo plus lifestyle.

    “Another RCT by Ladson et al. 36 on 22 adolescents, comparing BMI changes among participants with metformin and lifestyle to those with placebo and lifestyle found no significant differences in BMI (Table SC).”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

2 of the 27 references couldn’t be matched to a known paper.

Cited by

Sorted by citations

Authors
Ladson, G., Dodson, W. C., Sweet, S. D., Archibong, A. E., Kunselman, A. R., Demers, L. M., Lee, P. A., Williams, N. I., Coney, P., & Legro, R. S.
Affiliations
  • Meharry Medical College (US)
  • Pennsylvania State University (US)
  • Virginia Commonwealth University (US)
Corresponding author
Legro, Richard S.
Venue
Fertility and Sterility
Publisher
Elsevier BV
Published
2011-06
Volume
95
Issue
8
Pages
2595-2598.e6
ISSN
0015-0282 (ISSN-L)
OpenAlex
W2074835877
Cited by
56
References
27
Citations by year
2026: 2 · 2025: 4 · 2024: 2 · 2023: 4 · 2022: 3 · 2021: 5 · 2020: 7 · 2019: 5 · 2018: 3 · 2017: 2 · 2016: 3 · 2015: 4 · 2014: 7 · 2013: 2 · 2012: 2
FWCI
4.29
Type
journal article
Language
en
Open access
Locations
  • Fertility and Sterility (publishedVersion)
  • PubMed (publishedVersion)
  • Europe PMC (PubMed Central) (acceptedVersion)
  • PubMed Central (acceptedVersion)
Funders
Pennsylvania State University
Topics
  • Health Sciences › Medicine › Reproductive Medicine › Ovarian function and disorders
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic and Kidney Cyst Diseases
  • Health Sciences › Medicine › Reproductive Medicine › Endometriosis Research and Treatment
Keywords
metformin, polycystic ovary syndrome, adolescents, lifestyle therapy, hyperandrogenism, gastrointestinal adverse effects, quality of life, insulin sensitizers
MeSH terms
Adolescent, Combined Modality Therapy, Double-Blind Method, Exercise Therapy, Female, Humans, Metformin, Pilot Projects, Polycystic Ovary Syndrome, Quality of Life, Regression Analysis, Risk Factors, Testosterone, Time Factors, United States, Biomarkers, Treatment Outcome, Risk Assessment, Caloric Restriction, Risk Reduction Behavior

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review